Literature DB >> 6173124

Potentiation of bleomycin toxicity by oxygen.

C H Toledo, W E Ross, C I Hood, E R Block.   

Abstract

The clinical usefulness of bleomycin is limited by pulmonary toxicity. Recent clinical observations indicate that the pulmonary toxicity is potentiated in patients who are exposed to elevated but nontoxic concentrations of O2. We studied the interactions of O2 and bleomycin using a murine model. Mice were divided into two groups. One group was continuously exposed to 40% O2 at 1 atmosphere while the other group breathed compressed room air. The elevated O2 concentration alone was not toxic to animals. Mice in each group received either 40 mg/kg of bleomycin or normal saline twice a week sc. Median survival of mice receiving bleomycin was shortened from 8.24 to 4.35 weeks when the animals were maintained on 40% O2 (P = 0.0001). We conclude that exposure to a nontoxic but elevated O2 concentration can potentiate the toxic effects of bleomycin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6173124

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  5 in total

Review 1.  Drug-induced pulmonary vascular disease--mechanisms and clinical patterns.

Authors:  K Kumar; W E Holden
Journal:  West J Med       Date:  1986-09

Review 2.  Pulmonary toxicity of antineoplastic agents: anaesthetic and postoperative implications.

Authors:  D S Klein; P R Wilds
Journal:  Can Anaesth Soc J       Date:  1983-07

3.  Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case report.

Authors:  Sanjaykumar Hapani; David Chu; Shenhong Wu
Journal:  J Med Case Rep       Date:  2010-04-29

4.  Efficacy of Intralesional Bleomycin in Palmo-plantar and Periungual Warts.

Authors:  Prasoon Soni; Kanika Khandelwal; Naushin Aara; Bhikam C Ghiya; Rajesh D Mehta; Ram A Bumb
Journal:  J Cutan Aesthet Surg       Date:  2011-09

Review 5.  Imaging 'the lost tribe': a review of adolescent cancer imaging. Part 2: imaging of complications of cancer treatment.

Authors:  I Zerizer; P D Humphries
Journal:  Cancer Imaging       Date:  2009-11-06       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.